Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Galapagos NV

< Previous 1 2 Next >
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
From Galapagos NV
Via GlobeNewswire
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
From Galapagos NV
Via GlobeNewswire
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
From Galapagos NV
Via GlobeNewswire
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
From Galapagos NV
Via GlobeNewswire
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts
From Galapagos NV
Via GlobeNewswire
Galapagos Announces Executive Leadership Updates
From Galapagos NV
Via GlobeNewswire
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025
From Galapagos NV
Via GlobeNewswire
Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting
From Galapagos NV
Via GlobeNewswire
Galapagos receives transparency notification and 13D filing from Tang Capital
From Galapagos NV
Via GlobeNewswire
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
From Galapagos NV
Via GlobeNewswire
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities
From Galapagos NV
Via GlobeNewswire
Galapagos to Present at Upcoming Investor Conferences
From Galapagos NV
Via GlobeNewswire
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Galapagos NV
Via GlobeNewswire
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
From Galapagos NV
Via GlobeNewswire
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
From Galapagos NV
Via GlobeNewswire
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
From Galapagos NV
Via GlobeNewswire
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
From Galapagos NV
Via GlobeNewswire
Galapagos receives transparency notification from EcoR1 Capital
From Galapagos NV
Via GlobeNewswire
Galapagos receives transparency notification from EcoR1 Capital
From Galapagos NV
Via GlobeNewswire
Galapagos receives transparency notification from FMR LLC
From Galapagos NV
Via GlobeNewswire
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
From Galapagos NV
Via GlobeNewswire
Galapagos receives transparency notification from FMR LLC
From Galapagos NV
Via GlobeNewswire
Galapagos reports half-year 2024 financial results and provides second quarter business update
From Galapagos NV
Via GlobeNewswire
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
From Galapagos NV
Via GlobeNewswire
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
From Galapagos NV
Via GlobeNewswire
Galapagos creates new subscription right plans
From Galapagos NV
Via GlobeNewswire
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
From Galapagos NV
Via GlobeNewswire
Galapagos reports first quarter 2024 financial results
From Galapagos NV
Via GlobeNewswire
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
From Galapagos NV
Via GlobeNewswire
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
From Galapagos NV
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.